Pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome is an autoinflammatory disease characterized by destructive inflammation of the skin and joints in association with genetic mutation of the Pombe Cdc15 homology family member PSTPIP1. Because a therapeutic strategy specific to this disease has not been established, treatment is always challenging for clinicians. We herein describe a case of PAPA syndrome with typical clinical features successfully treated with combination therapy of traditional anti-inflammatory drugs. A 39-year-old man presented with painful plaques on his extremities that had been present for several years. Large brown plaques were observed on both arms and legs with numerous fistulae and ulcers. Cystic acne lesions subsequently appeared on his cheeks and upper back. We diagnosed the patient with PAPA syndrome based on the presence of typical clinical features; however, no genetic mutations of exon-1 to 15 of PSTPIP1 were found. Although recent reports have emphasized the efficacy of biologics that target inflammatory cytokines such as antibodies to interleukin-1β and tumor necrosis factor-α, use of these agents remains uncovered by health insurance in Japan, showing unresolved discrepancy in practical use for clinicians. The present patient was successfully treated with combined therapy of a corticosteroid, colchicine, and cyclosporine A, encouraging the use of this combination therapy as a novel therapeutic option.
Introduction
Pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome is an autoinflammatory disease characterized by destructive inflammation of the skin and joints [1] in association with genetic mutation of the Pombe Cdc15 homology family member PSTPIP1 [2, 3] . This is an extremely rare disease as the prevalence is estimated less than one per million. Because a therapeutic strategy specific to this disease has not been established except for anecdotal systemic administration of corticosteroids, treatment is always challenging for clinicians. We herein describe a case of PAPA syndrome with typical clinical features successfully treated with combination therapy of traditional antiinflammatory drugs.
Case Presentation
A 39-year-old man presented with painful plaques on his extremities that had been present for several years. He had no history of autoimmune disorders or hematological disorders and no family history of such skin lesions. Cystic acne lesions appeared on his cheeks and upper back ( Figure 1A) . Large brown plaques were observed on both arms and legs with numerous fistulae and ulcers ( Figure 1B) . A skin biopsy of an arm lesion revealed nonspecific inflammatory infiltrates comprising neutrophils and lymphocytes. The multiple cystic acne lesions later deteriorated with simultaneous emergence of a lowgrade fever and arthralgia of both knees and ankles. Neither bacteria nor fungi grew in cultures of discharge from the arm lesions and serous fluid from a fine needle aspiration of the right knee joint. We diagnosed the patient with PAPA syndrome based on the presence of typical clinical features; however, no genetic mutations of exon-1 to 15 of PSTPIP1 were found. Laboratory investigation revealed leukocytosis with neutrophilia and elevated levels of serum C-reactive protein in parallel with the disease severity (Figure 2) . The serum interleukin-1β and tumor necrosis factor-α levels were within the normal range at different two time points (IL-1β, 0.4 pg/mL and <0.2 pg/mL, [normal range, <10 pg/mL]; TNF-α, 2.1 pg/mL and 0.8. pg/mL, [normal range, 0.6-2.8 pg/mL]). The activities of phagocytosis and reactive oxygen species production in neutrophils were lower than those in normal individuals. The natural killer cell activity, which was evaluated by Cr release assay 12 hours after co-culture of circulating mononuclear cells (as effector cells) and Cr-labeled K562 cell line (as target cells), was 5.9% (normal range, 8.9%-29.5%) and 8.6% (17.1%-48.7%) in 10:1 and 20:1 of effector cells:target cells, respectively. The patient was hospitalized for treatment; however, monotherapy with an antiinflammatory agent (corticosteroid, cyclosporine A, etretinate, or minocycline) could not control the disease activity. Therefore, we tried various combinations of multiple anti-inflammatory agents. Finally, we found that the combination of a systemic corticosteroid (prednisolone at 10-15 mg/day) with cyclosporine A (100 mg/day) and colchicine (1 mg/ day) achieved alleviation of the patient's PAPA syndrome, resulting in complete resolution at least >4 years after initiation of this combination therapy ( Figures 1B, 1D and 2 ).
Discussion
Immunological aberrance associated PSTPIP1 gene mutation-linked inflammasomes is considered the hallmark abnormality in most cases of PAPA syndrome [3] . However, four cases of PAPA syndrome without PSTPIP1 gene mutations have been reported [4] , including the present case, suggesting that PSTPIP1 gene mutations are not a prerequisite for the clinical manifestations of PAPA syndrome. Instead, we found defects in natural killer cell activity in the present case; such defects have not been previously found and might be involved in the pathogenesis of PAPA syndrome from a novel immunological viewpoint. However, further investigation is required. Although recent reports have emphasized the efficacy of biologics that target inflammatory cytokines such as antibodies to interleukin-1β and tumor necrosis factor-α [5, 6] , use of these agents remains uncovered by health insurance in Japan, showing unresolved discrepancy in practical use for clinicians. Conversely, several trials of various treatments have been reported, including corticosteroids, immunosuppressant, and antibiotics, and the efficacy of the combination of corticosteroids and immunosuppressants remains equivocal. The present patient was successfully treated with combined therapy of a corticosteroid, colchicine, and cyclosporine A, encouraging the use of this combination therapy as a novel therapeutic option.
Conclusion
The present case was successfully treated with combined therapy of a corticosteroid, colchicine, and cyclosporine A, suggestive of a novel treatment option for PAPA syndrome.
